Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.7.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Revenues $ 37 $ 379 $ 247 $ 673
Operating expenses:        
Research and development (related party of $225, $244, $670 and $723), net of grant income of ($44, $7, $84 and $7) 1,136 1,048 3,005 2,303
General and administrative (related party of $191, $303, $553 and $395) 2,837 2,403 7,657 5,509
Total operating expenses 3,973 3,451 10,662 7,812
Operating loss (3,936) (3,072) (10,415) (7,139)
Other income (expense):        
Interest expense (related party of $481, $323, $1,447 and $323) (481) (323) (1,447) (323)
Interest income 8 5 33 9
Royalty income 4 5 20 17
Total other income (expense) (469) (313) (1,394) (297)
Consolidated net loss (4,405) (3,385) (11,809) (7,436)
Net loss attributable to noncontrolling interest 492 349 1,606 349
Net loss attributable to iBio, Inc. (3,913) (3,036) (10,203) (7,087)
Preferred stock dividends (26) 0 (26) 0
Net loss available to iBio, Inc. (3,939) (3,036) (10,229) (7,087)
Comprehensive loss:        
Consolidated net loss (4,405) (3,385) (11,809) (7,436)
Other comprehensive income (loss) - foreign currency translation adjustments 0 2 0 (6)
Comprehensive loss $ (4,405) $ (3,383) $ (11,809) $ (7,442)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.04) $ (0.11) $ (0.09)
Weighted-average common shares outstanding - basic and diluted 89,109 81,158 89,109 78,587